Abstract. Although plumbagin, a natural naphthoquinone, has exhibited antiproliferative activity in numerous types of cancer, its anticancer potential in esophageal squamous cell carcinoma (EScc) remains unclear. In the present study, the effect of plumbagin on the growth of EScc cells was investigated in vitro and in vivo. EScc cells were treated with plumbagin and tested for cell cycle distribution and apoptosis. The involvement of STAT3 signaling in the effect of plumbagin was examined. The results demonstrated that plumbagin treatment suppressed EScc cell viability and proliferation, yet normal esophageal epithelial cell viability was not affected. Plumbagin treatment increased the proportion of cells in the G 0 /G 1 phase of the cell cycle and decreased the proportion of cells in the S phase. Furthermore, plumbagin-treated EScc cells displayed a significantly greater % of apoptotic cells. Western blot analysis confirmed that plumbagin upregulated tumor protein p53 and cyclin-dependent kinase inhibitor 1A (also known as p21), while it downregulated cyclin d1, cyclin-dependent kinase 4, and induced myeloid leukemia cell differentiation protein Mcl-1. Mechanistically, plumbagin inhibited STAT3 activation, and overexpression of constitutively active STAT3 reversed the plumbagin-mediated growth suppression in EScc cells. In vivo studies demonstrated that plumbagin delayed the growth of EScc xenograft tumors and reduced STAT3 phosphorylation. Overall, plumbagin was demonstrated to target STAT3 signaling and to inhibit the growth of EScc cells both in vitro and in vivo, suggesting that it may represent a potential anticancer agent for EScc.
Introduction
Esophageal carcinoma, and in particular the histological subtype esophageal squamous cell carcinoma (EScc), is frequently detected in developing countries including china (1, 2) . At present, the main treatment options available for EScc include radical esophagectomy, radiotherapy and chemotherapy. despite advances in therapeutic approaches, the 5-year survival rate of EScc remains very low (3, 4) . Therefore, it is of importance to develop novel therapeutic modalities for EScc.
Plumbagin (Fig. 1A) is a natural naphthoquinone that is widely distributed in the family of Plumbaginaceae. Plumbagin exhibits multiple biological properties, including antibacterial (5), antimalarial (6) , anti-inflammatory (7) , and antitumor (8) activities. It has been documented that plumbagin inhibits the invasion of breast cancer cells by inactivating signal transducer and activator of transcription 3 (STAT3) signaling (8) . Likewise, plumbagin has been demonstrated to target the STAT3 pathway to block the growth of pancreatic cancer cells (9) . STAT3 is a key transcription regulator that is aberrantly activated in EScc (10, 11) . It has been reported that knockdown of STAT3 reduces the proliferation of EScc cells (11) , indicating the requirement for STAT3 activation in the progression of EScc. Given the inhibitory activity of plumbagin on STAT3 signaling, the present study hypothesized that plumbagin may exert anticancer effects against EScc.
To test this hypothesis, in the present study EScc cells were treated with different concentrations of plumbagin and the effects of plumbagin on cell proliferation, cell cycle progression and apoptosis were examined in vitro. In addition, the in vivo effect of plumbagin on the growth of EScc xenograft tumors was investigated. Furthermore, the potential involvement of STAT3 signaling in the activity of plumbagin in EScc cells was examined. Cell viability assay. cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. In brief, following plumbagin treatment, cells were incubated with 0.5 mg/ml MTT (Sigma-Aldrich; Merck KGaA) at 37˚C for 4 h, followed by the addition of DMSO. The absorbance of the MTT formazan reduction product was measured at 570 nm.
Materials and methods

Cell
Cell proliferation assay. cell proliferation was measured using 5-bromo-2'-deoxyuridine (BrdU) incorporation assay (13 Cell transfection and luciferase reporter assay. For overexpression of constitutively active STAT3, EScc cells were seeded 12 h prior to transfection. At 80% confluence, they were transfected with pSTAT3-c or empty vector using Lipofectamine 2000 following the manufacturer's instructions (Invitrogen; Thermo Fisher Scientific, Inc.). At 24 h after transfection, cells were treated with plumbagin and subjected to proliferation and apoptosis assays. For the luciferase reporter assay, EScc cells were co-transfected with pSTAT3-Luc (0.5 µg) and pRL-TK (20 ng) 24 h prior to plumbagin treatment. Following incubation for an additional 48 h, cells were lysed and luciferase activities were measured using a luciferase assay kit (Promega corporation). The firefly luciferase activity was normalized to that of Renilla luciferase.
Animal experiments. For xenograft studies, a total of 10 male nude mice (aged 4-6 weeks) were used, which were purchased from the Experimental Animal center of Zhengzhou University (Zhengzhou, china). Animals were housed in a laminar air flow hood under a 12/12 h light/dark cycle at 25˚C and 50% humidity with free access to food and water. EcA-109 and TE-1 cells (2x10 6 cells/mouse) were subcutaneously injected into the flanks of mice. When xenograft tumors reached 100 mm 3 , the tumor-bearing mice (n=5 for each group) were intraperitoneally administered with plumbagin or vehicle (0.05% DMSO) at a dose of 2 mg/kg/day 3 times per week for 4 weeks (14) . Tumor growth was monitored by measuring tumor volume. All animals were sacrificed after 30 days of treatment. Tumors were removed and processed for immunohistochemical staining using anti-Ki-67 (cat. no. ab15580; 1:500; Abcam) and anti-phospho-STAT3 (1:100) antibodies (15) . Over 1,000 cells were counted from 5 random microscopic fields, and the % of immunoreactive cells was calculated. All experiments involving animals were approved by the Experimental Animal Ethics committee of Shanghai Jiao Tong University School of Medicine (Shanghai, china; Approval number: 2016-01-032).
Statistical analysis. data are presented as the mean ± standard deviation. Statistical differences were determined using the Student's t-test for comparison of two groups or one-way analysis of variance followed by Tukey's post-hoc test for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.
Results
Plumbagin inhibits the viability and proliferation of ESCC cells in vitro.
To assess the cytotoxicity of plumbagin, two EScc cell lines were exposed to different concentrations of plumbagin for 48 h. As determined by MTT assay (Fig. 1B) , plumbagin treatment resulted in a concentration-dependent reduction in cell viability. The Ic 50 values for plumbagin in EcA-109 and TE-1 cells were 6.2±0.5 and 2.4±0.6 µM, respectively. BrdU incorporation assay was preformed to validate the antiproliferative activity of plumbagin. The results demonstrated that treatment with 8 µM plumbagin for 48 h decreased the proliferation of EcA-109 and TE-1 cells by 45.5 and 62.6%, respectively (Fig. 1C) . However, plumbagin, up to the concentration of 16 µM, had no significant impact on the viability of normal esophageal epithelial cells following treatment for 48 h (Fig. 1d) .
Plumbagin induces cell cycle arrest at the G 0 /G 1 phase and triggers apoptosis in ESCC cells.
Flow cytometric analysis was performed to determine the effect of plumbagin on cell cycle progression and apoptosis. As presented in Fig. 2A , treatment of EcA-109 cells with plumbagin for 48 h increased the proportion of cells in the G 0 /G 1 phase of the cell cycle from 50 to 62% (P= 0.001) and decreased the proportion of cells in the S phase from 29 to 18% (P= 0.002) relative to control. In addition, plumbagin treatment resulted in a 4.7-fold (P=0.004) increase in the % of Annexin V-positive apoptotic cells, compared with vehicle-treated cells (Fig. 2B) . Similar findings were observed in TE-1 cells following treatment with plumbagin (Fig. 2) . Western blot analysis of several key genes involved in cell cycle progression and apoptosis confirmed that plumbagin treatment resulted in a marked increase in p53 and p21 and decrease in cyclin d1, cdK4 and Mcl-1 expression (Fig. 3A) . In addition, cleavage of caspase-3 and PARP was markedly enhanced in plumbagin-treated EcA-109 and TE-1 cells compared with vehicle-treated cells (Fig. 3A) .
Plumbagin inhibits the STAT3 signaling pathway.
Western blot analysis demonstrated that plumbagin treatment led to a significant decrease in the levels of phosphorylated STAT3, but not total STAT3 protein (Fig. 3B) . consistently, plumbagin-treated EScc cells displayed a 3-to 6-fold reduction of STAT3 reporter gene activity, compared with control cells (Fig. 3c) . These data indicated that plumbagin had the capacity to interfere with STAT3 activation.
Overexpression of constitutively active STAT3 reverses plumbagin-mediated growth suppression. Next, the hypothesis that the plumbagin-mediated cytotoxicity in EScc cells was directly associated with inactivation of STAT3 signaling was examined. To this end, rescue experiments were performed with a constitutively active STAT3 variant. The results demonstrated that ectopic expression of constitutively active STAT3 (Fig. 4A ) significantly attenuated the plumbagin-induced growth suppression (Fig. 4B) and apoptosis (Fig. 4c) in EScc cells.
Plumbagin suppresses the growth of ESCC xenografts in mice.
To determine the in vivo anticancer effect of plumbagin, EcA-109 and TE-1 cells were injected into nude mice, allowed to form xenograft tumors, and treated with plumbagin or vehicle in vivo. After 30 days, plumbagin-treated EcA-109 and TE-1 xenograft tumors displayed 72 and 54% reduction in tumor volume, respectively, relative to vehicle-treated tumors (Fig. 5A) . Immunohistochemistry analysis of tumor specimens confirmed that plumbagin-treated tumors presented a significant reduction in the % of Ki-67-positive cells (P=0.011; Fig. 5B) . Additionally, the levels of phosphorylated STAT3 were significantly lower in plumbagin-treated tumors compared with vehicle-treated tumors (P=0.001; Fig. 5c ).
Discussion
Plumbagin has exhibited anticancer properties in many types of cancer, including breast cancer (8) , pancreatic cancer (9), prostate cancer (16) , and gastric cancer (17) . It has been reported that plumbagin can block prostate carcinogenesis triggered by loss of phosphatase and tensin homolog (PTEN) (16) . Similarly, plumbagin treatment resulted in a significant inhibition of tumorigenesis and angiogenesis in ovarian cancer xenograft models (14) . In the present study, plumbagin was also confirmed to exert growth suppressive effects against EScc cells. Treatment with plumbagin led to a significant decline in cell viability and proliferation in ESCC cells. Plumbagin-mediated toxicity appeared to be selective to malignant cells, as the viability of a normal esophageal epithelial cell line was not significantly changed following plumbagin treatment. In agreement with the present findings, a previous study has demonstrated that plumbagin was more effective at killing melanoma cells than non-malignant cells in vitro and that it displayed negligible toxicity to normal organs in vivo (18) . To gain more insight into the growth suppression induced by plumbagin, the effects of plumbagin on cell cycle distribution and apoptosis were analyzed. Plumbagin-treated EScc cells displayed an accumulation of G 0 /G 1 -phase cells and significant apoptotic death, compared with vehicle-treated cells. At the molecular level, multiple genes, including p53, p21, cyclin d1, cdK4 and Mcl-1 were deregulated in response to plumbagin treatment. The protein p21 is a well-defined CDK inhibitor that can bind to cyclin/cdK complexes and inhibit their catalytic activities (19) . p53 acts as a tumor suppressor and has the ability to induce cell cycle arrest and apoptosis (20) , while Mcl-1 serves an important role in protecting cells from apoptosis (21) . Taken together, plumbagin treatment was demonstrated to modulate many key genes involved in the regulation of cell cycle progression and apoptosis, consequently leading to cell cycle arrest and apoptosis. Such effects were also previously reported in breast cancer (22) and colon cancer cells (23) . It should be mentioned that the suppressive activity of plumbagin appears not to be G 1 -phase specific, as this compound can cause G 2 /M-phase arrest in A549 lung cancer cells (24) .
Targeting STAT3 signaling represents an important molecular mechanism for the anticancer activity of plumbagin in melanoma (18) , gastric cancer (17), breast cancer (8) , and prostate cancer (25) . In line with these studies, the present data demonstrated that plumbagin treatment significantly suppressed STAT3 activation in EScc cells. STAT3 has been reported to regulate many genes involved in cell proliferation and survival, including cyclin d1, Bcl-2, Mcl-1, and cellular inhibitor of apoptosis 2 (c-IAP2) (26, 27) . consistent with the inactivation of STAT3, the expression of cyclin d1 and Mcl-1 was downregulated in EScc cells in response to plumbagin treatment. Rescue experiments provided further evidence for the involvement of STAT3 signaling in the anticancer activity of plumbagin in EScc. In vivo studies demonstrated that plumbagin treatment significantly delayed the growth of established ESCC xenograft tumors and suppressed STAT3 phosphorylation. collectively, plumbagin exerted its growth suppressive activity in EScc by targeting STAT3 signaling, which may provide an explanation for selective inhibition of cancer cells. It was reported that plumbagin can inhibit A549 lung cancer cell growth by inactivating c-Jun N-terminal kinase signaling (24) . Therefore, it is possible that multiple signaling pathways other than STAT3 are involved in the anticancer activity of plumbagin in EScc.
In conclusion, the present data reinforce that plumbagin has growth suppressive activity against EScc cells, which is, at least in part, mediated through inhibition of STAT3 activation. These findings suggest that plumbagin may be a promising anticancer agent for EScc.
